Susana Otero‐Romero

Defining high, medium and low impact prognostic factors for developing multiple sclerosis

Mar Tintoré, Àlex Rovira, Jordi Río et al. · Brain · 2015 · 505 citations

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia, Antonio J. Carcas, Mayte Pérez‐Olmeda et al. · The Lancet · 2021 · 384 citations · Full text

Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis

Carmen Tur, Pere Carbonell‐Mirabent, Álvaro Cobo‐Calvo et al. · JAMA Neurology · 2022 · 245 citations · Full text

COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response

Ana Zabalza, Simón Cárdenas‐Robledo, Paula Tagliani et al. · European Journal of Neurology · 2020 · 137 citations

Retinal microvascular abnormalities in patients after COVID-19 depending on disease severity

Miguel Ángel Zapata, Sandra Banderas García, Adrián Sánchez-Moltalvá et al. · British Journal of Ophthalmology · 2020 · 99 citations · Full text